Literature DB >> 11529288

Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis.

J Navarro1, M Rainisio, H K Harms, M E Hodson, C Koch, G Mastella, B Strandvik, S G McKenzie.   

Abstract

The European Epidemiologic Registry of Cystic Fibrosis began collecting longitudinal data on European cystic fibrosis patients in 1994. A cross-sectional analysis was performed to identify the factors associated with low values of % predicted forced expiratory volume in one second (FEV1) upon patient enrollment. Data from 7,010 patients aged > or =6 yrs were included. Clinical conditions, microbiological isolates and medications reported at enrollment or within the following 180 days were analysed for age-specific associations. Factors associated with FEV1 that were lower by >10% of pred values were: lower weight for age percentiles, haemoptysis, pneumothorax, pulmonary symptoms at presentation, Pseudomonas aeruginosa, Burkholderia cepacia, oral corticosteroids, nonsteroid anti-inflammatory drugs, dornase alfa, oxygen and assisted ventilation and, in patients >12 yrs old only, use of airway clearance techniques, inhaled bronchodilators, oral nutritional supplements, pancreatic enzymes and insulin or oral hypoglycaemics. Slightly impaired lung function (5-10%) was associated with: diabetes (> or = 18-yrs-old), gastro-oesophageal reflux, allergic bronchopulmonary aspergillosis, asthma-like symptoms, portal hypertension, Aspergillus spp. and Candida spp. Sex, Haemophilus influenzae and Staphylococcus aureus were not associated with impaired pulmonary status. Regular exercise (especially in older patients) and nasal polyposis were associated with slightly better FEV1. The results confirm those of previous studies and suggest selective prescribing in sicker patients.

Entities:  

Mesh:

Year:  2001        PMID: 11529288     DOI: 10.1183/09031936.01.00068901

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  43 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Authors:  Juyan Zhou; Yunhua Chen; Setareh Tabibi; Luis Alba; Elizabeth Garber; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Gastroesophageal reflux causing nutritional failure and vomiting in a teenager with cystic fibrosis and respiratory failure.

Authors:  Alexandra Higton; Sarah Collins; Diana Bilton
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

Review 5.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

Review 6.  Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.

Authors:  Andoni Ramirez-Garcia; Aize Pellon; Idoia Buldain; Aitziber Antoran; Aitana Arbizu-Delgado; Xabier Guruceaga; Aitor Rementeria; Fernando L Hernando
Journal:  Mycopathologia       Date:  2017-05-08       Impact factor: 2.574

7.  Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings.

Authors:  I Bronsveld; F Mekus; J Bijman; M Ballmann; H R de Jonge; U Laabs; D J Halley; H Ellemunter; G Mastella; S Thomas; H J Veeze; B Tümmler
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Aspergillus Bronchitis in Patients with Cystic Fibrosis.

Authors:  Claudia Brandt; Jobst Roehmel; Volker Rickerts; Volker Melichar; Nadja Niemann; Carsten Schwarz
Journal:  Mycopathologia       Date:  2017-08-17       Impact factor: 2.574

Review 9.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

Review 10.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.